Genscript Biotech Corporation (HKG:1548)
Hong Kong · Delayed Price · Currency is HKD 34.44
+1.08 (3.24%)
Aug 21, 2026, 4:08 PM HKT
Genscript Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 844.97 | 959.53 | 594.49 | 560.48 | 625.7 | 490.1 | |
Revenue Growth | 2.04% | 61.40% | 6.07% | -10.42% | 27.67% | 25.39% |
Cost of Revenue | 405.69 | 406.32 | 322.36 | 289.85 | 321.62 | 207.58 |
Gross Profit | 439.28 | 553.2 | 272.13 | 270.63 | 304.08 | 282.52 |
Selling, General & Admin | 234.53 | 228.06 | 202.5 | 186.96 | 350.81 | 302.48 |
Research & Development | 79.35 | 71.23 | 53.79 | 52.7 | 390.1 | 358.4 |
Operating Expenses | 313.58 | 297.96 | 262.84 | 244.44 | 742.06 | 661.81 |
Operating Income | 125.7 | 255.25 | 9.28 | 26.19 | -437.98 | -379.29 |
Interest Expense | -14.48 | -17.29 | -8.03 | -5.74 | -13.27 | -2.38 |
Interest & Investment Income | 25.4 | 26.1 | 29.38 | 22.58 | 13.22 | 6.55 |
Earnings From Equity Investments | -281.93 | -320.38 | -39.07 | -1.38 | - | - |
Currency Exchange Gain (Loss) | -36.4 | -13.05 | 0.64 | 2.54 | - | - |
Other Non Operating Income (Expenses) | 6.79 | 20.55 | 5.92 | 5.38 | -0.96 | -3.52 |
EBT Excluding Unusual Items | -174.92 | -48.82 | -1.89 | 49.58 | -438.98 | -378.63 |
Impairment of Goodwill | - | - | - | - | -11.48 | - |
Gain (Loss) on Sale of Investments | -414.91 | -421.72 | -123.4 | 130.97 | 18.77 | -138.73 |
Asset Writedown | - | - | -45.51 | -11.66 | - | - |
Pretax Income | -589.83 | -470.53 | -170.8 | 168.89 | -431.69 | -517.36 |
Income Tax Expense | 47.37 | 61.87 | 2.98 | 6.01 | -3.72 | 0.96 |
Earnings From Continuing Operations | -637.2 | -532.4 | -173.77 | 162.88 | -427.97 | -518.33 |
Earnings From Discontinued Operations | - | - | 3,029 | -518 | - | - |
Net Income to Company | -637.2 | -532.4 | 2,855 | -355.12 | -427.97 | -518.33 |
Minority Interest in Earnings | 0.49 | -0.43 | 106.59 | 259.64 | 201.12 | 159.62 |
Net Income | -636.71 | -532.83 | 2,962 | -95.48 | -226.85 | -358.71 |
Net Income to Common | -636.71 | -532.83 | 2,962 | -95.48 | -226.85 | -358.71 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 2,182 | 2,167 | 2,121 | 2,109 | 2,097 | 2,031 |
Shares Outstanding (Diluted) | 2,182 | 2,192 | 2,178 | 2,109 | 2,097 | 2,031 |
Shares Change | -0.75% | 0.63% | 3.27% | 0.58% | 3.28% | 6.83% |
EPS (Basic) | -0.29 | -0.25 | 1.40 | -0.05 | -0.11 | -0.18 |
EPS (Diluted) | -0.29 | -0.25 | 1.40 | -0.05 | -0.11 | -0.18 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 6.52 | 243.39 | -120.14 | -539.36 | -336.41 | -269.83 |
Free Cash Flow Per Share | 0.00 | 0.11 | -0.06 | -0.26 | -0.16 | -0.13 |
Gross Margin | 51.99% | 57.65% | 45.77% | 48.28% | 48.60% | 57.65% |
Operating Margin | 14.88% | 26.60% | 1.56% | 4.67% | -70.00% | -77.39% |
Profit Margin | -75.35% | -55.53% | 498.22% | -17.04% | -36.26% | -73.19% |
Free Cash Flow Margin | 0.77% | 25.36% | -20.21% | -96.23% | -53.76% | -55.06% |
EBITDA | 192.65 | 317.61 | 70.04 | 83.5 | -388.9 | -341.57 |
EBITDA Margin | 22.80% | 33.10% | 11.78% | 14.90% | -62.15% | -69.69% |
D&A For EBITDA | 66.94 | 62.36 | 60.75 | 57.3 | 49.08 | 37.72 |
EBIT | 125.7 | 255.25 | 9.28 | 26.19 | -437.98 | -379.29 |
EBIT Margin | 14.88% | 26.60% | 1.56% | 4.67% | -70.00% | -77.39% |
Effective Tax Rate | - | - | - | 3.56% | - | - |